Nanoparticle-Based Biosensing Assay for Universally Accessible Low-Cost TB Detection with Comparable Sensitivity as Culture
Instituto de Investigacion en Ciencia y Tecnologia, Universidad Cesar Vallejo, Trujillo 13100, Peru
Hospital Victor Lazarte Echegaray, Trujillo 13100, Peru
Institute for Global Health, Michigan State University, East Lansing, MI 48824, USA
Kingman Regional Medical Center, Kingman, AZ 86409, USA
Global Alliance for Rapid Diagnostics, Michigan State University, East Lansing, MI 48824, USA
Biosystems and Agricultural Engineering, Michigan State University, East Lansing, MI 48824, USA
Author to whom correspondence should be addressed.
Diagnostics 2019, 9(4), 222; https://doi.org/10.3390/diagnostics9040222
Received: 12 November 2019 / Revised: 6 December 2019 / Accepted: 11 December 2019 / Published: 13 December 2019
(This article belongs to the Special Issue Biosensors-Based Diagnostics)
Tuberculosis (TB) is the leading cause of death globally, surpassing HIV. Furthermore, multidrug-resistant and extensively drug-resistant TB have become global public health threats. Care of TB patients starts with quality, accessible, and affordable diagnosis. The study presents a novel technique called nanoparticle-based colorimetric biosensing assay (NCBA) based on the principles of magnetically activated cell enrichment. A total of 1108 sputum samples were subjected to sputum smear microscopy (SSM), NCBA, and standard culture. SSM and NCBA were completed in 20 min; culture was completed in 8 weeks. Results show that NCBA has matching sensitivity of 100.0% and specificity of 99.7% compared to the gold standard culture method at a cost of $0.50/test based on Peruvian conditions. Sputum smear microscopy has 63.87% sensitivity compared to culture. NCBA has the potential of being used in local health clinics as it only requires a microscope that is widely available in many rural areas. Because NCBA could detect low levels of bacterial load comparable to culture, it could be used for rapid and early TB-onset detection. The gain in time is critical as TB is airborne and highly infectious, minimizing contact exposure. Early detection could lead to early treatment, while the patient’s immune system is still high. The low cost makes NCBA affordable and accessible to those who need them the most.